Xanthus Will Develop Oral Fludarabine For U.S. Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering AG opts to out-license the oncologic rather than invest in further clinical study to support U.S. approval of the new dosage form.
You may also be interested in...
NICE Recommends Against Fludarabine For First-Line Treatment Of CLL
Final Appraisal Determination concludes that Fludara monotherapy is not cost effective compared to chlorambucil.
NICE Recommends Against Fludarabine For First-Line Treatment Of CLL
Final Appraisal Determination concludes that Fludara monotherapy is not cost effective compared to chlorambucil.
Xanthus To Develop Lung Cancer Therapy Following Deal With Schering AG
Xanthus licenses the peptide PD045, which management originally developed at Diatide prior to acquisition by Schering AG.